DSIJ Mindshare

Rs 165,19,95,596 lost in just 1 month; Rekha Rakesh Jhunjhunwala's bet on this small-cap loss-making company goes wrong, do you own it?

Blindly mirroring the portfolio of an Ace investor can potentially destroy the wealth of a retail investor who has limited capital to invest.

Rakesh Deshmukh 0 12695 Article rating: 3.8

FIIs have reduced their stake with DIIs maintaining a constant stake whereas the public investors' stake has increased in Q4 FY24.

Upcoming collaboration: Two leading pharma company stocks to watch out for

US FDA approved a benzyl alcohol and propylene glycol-free formulation to minimize gasping syndrome risk, for the treatment of seizures in newborns

Kiran Shroff 0 1989 Article rating: 4.5

Upcoming collaboration: Two leading pharma company stocks to watch out for                                                                                                                                                                                            US FDA approved a benzyl alcohol and propylene glycol-free formulation to minimize gasping syndrome risk, for the treatment of seizures in newborns.

RSS
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR